Post-discharge decolonization of patients harboring methicillin-resistant Staphylococcus aureus (MRSA) USA300 strains: secondary analysis of the CLEAR Trial

Infect Control Hosp Epidemiol. 2023 Feb;44(2):315-318. doi: 10.1017/ice.2021.482. Epub 2021 Dec 16.


The CLEAR Trial recently found that decolonization reduced infections and hospitalizations in MRSA carriers in the year following hospital discharge. In this secondary analysis, we explored whether decolonization had a similar benefit in the subgroup of trial participants who harbored USA300, using two different definitions for the USA300 strain-type.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aftercare
  • Carrier State / drug therapy
  • Humans
  • Methicillin-Resistant Staphylococcus aureus*
  • Patient Discharge
  • Staphylococcal Infections* / drug therapy
  • Staphylococcal Infections* / prevention & control